The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors…
The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors…